Literature DB >> 7501341

Effect of Candida albicans infection and clotrimazole treatment on vaginal microflora in vitro.

R A Ross1, M L Lee, A B Onderdonk.   

Abstract

OBJECTIVE: To determine the effect of Candida albicans infection and clotrimazole treatment on vaginal microflora.
METHODS: Studies were conducted using a model simulating the healthy vaginal ecosystem. The model consisted of a mixed culture of Lactobacillus acidophilus, Staphylococcus epidermidis, Prevotella bivia, and group D Streptococcus sp grown in continuous culture in a chemically defined medium. The status of the model was assessed using a mathematical equation that determines the probability a microflora is normal or abnormal.
RESULTS: Challenge of the model with C albicans was followed within 24 hours by the development of microbial populations representing an abnormal microflora. Treatment of the system with clotrimazole (100 micrograms/mL) resulted in a decrease in C albicans counts to 0 within 48 hours. However, treatment also altered other components of the vaginal microflora, which did not return to normal. Addition of clotrimazole (100 micrograms/mL) to the system in the absence of C albicans also resulted in an abnormal model by 24 hours.
CONCLUSIONS: Candida albicans infection of the vaginal ecosystem, as represented by this in vitro model, has a deleterious effect on members of the normal microflora. Clotrimazole, although effective against C albicans infection, also has a deleterious effect on components of the normal vaginal microflora. One of the implications for women using clotrimazole for microbiologically undocumented vaginal yeast infections is an increased risk of infection or disease through the disruption of the protective microflora barrier.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7501341     DOI: 10.1016/0029-7844(95)00318-l

Source DB:  PubMed          Journal:  Obstet Gynecol        ISSN: 0029-7844            Impact factor:   7.661


  7 in total

1.  Quantitative microbiologic models for preterm delivery.

Authors:  Andrew B Onderdonk; Mei-Ling Lee; Ellice Lieberman; Mary L Delaney; Ruth E Tuomala
Journal:  J Clin Microbiol       Date:  2003-03       Impact factor: 5.948

2.  A mucoadhesive, cyclodextrin-based vaginal cream formulation of itraconazole.

Authors:  Marc Francois; Eric Snoeckx; Peter Putteman; Fons Wouters; Eddy De Proost; Urbain Delaet; Jef Peeters; Marcus E Brewster
Journal:  AAPS PharmSci       Date:  2003

3.  Ethosomes and ultradeformable liposomes for transdermal delivery of clotrimazole: A comparative assessment.

Authors:  Rahul G S Maheshwari; Rakesh K Tekade; Piyoosh A Sharma; Gajanan Darwhekar; Abhishek Tyagi; Rakesh P Patel; Dinesh K Jain
Journal:  Saudi Pharm J       Date:  2011-10-31       Impact factor: 4.330

4.  Clinical Evaluation of a Self-Testing Kit for Vaginal Infection Diagnosis.

Authors:  Ching-Ju Shen; Chung-Yao Yang; Huan-Yun Chen; Wei-Chun Chen; Ting-Chang Chang; Chao-Min Cheng
Journal:  J Healthc Eng       Date:  2021-08-06       Impact factor: 2.682

5.  Comparison of Enzymatic Method Rapid Yeast Plus System with RFLP-PCR for Identification of Isolated Yeast from Vulvovaginal Candidiasis.

Authors:  Moallaei Hossein; Seied Hossein Mirhendi; João Brandão; Reza Mirdashti; Laura Rosado
Journal:  Iran J Basic Med Sci       Date:  2011-09       Impact factor: 2.699

6.  Improvement of solubility and dissolution properties of clotrimazole by solid dispersions and inclusion complexes.

Authors:  Gehan Balata; M Mahdi; Rania Abu Bakera
Journal:  Indian J Pharm Sci       Date:  2011-09       Impact factor: 0.975

7.  Improving appropriate use of antifungal medications: the role of an over-the-counter vaginal pH self-test device.

Authors:  Subir Roy; James C Caillouette; Joel S Faden; Tapon Roy; Diana E Ramos
Journal:  Infect Dis Obstet Gynecol       Date:  2003
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.